UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.307

Sortiert nach

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation

Leukemia, 2018-05, Vol.32 (5), p.1070-1080

2018

Volltextzugriff (PDF)

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia

Leukemia, 2015-10, Vol.29 (10), p.2015-2023

2015

Volltextzugriff (PDF)

131 INVITED Chronic Lymphocytic Leukaemia (CLL)

European journal of cancer (1990), 2011, Vol.47, p.S32-S32

Zenz, T

2011

Volltextzugriff (PDF)

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

Scientific reports, 2018-08, Vol.8 (1), p.12046-12, Article 12046

2018

Volltextzugriff (PDF)

The impact of SF3B1 mutations in CLL on the DNA-damage response

Leukemia, 2015-05, Vol.29 (5), p.1133-1142

2015

Volltextzugriff (PDF)

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Leukemia, 2012-07, Vol.26 (7), p.1458-1461

2012

Volltextzugriff (PDF)

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Haematologica (Roma), 2016-05, Vol.101 (5), p.531

2016

Volltextzugriff (PDF)

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

Leukemia, 2018-03, Vol.32 (3), p.774-787

2018

Volltextzugriff (PDF)

Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton

Leukemia, 2014-06, Vol.28 (6), p.1289-1298

2014

Volltextzugriff (PDF)

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus

Leukemia, 2017-08, Vol.31 (8), p.1686-1694

2017

Volltextzugriff (PDF)

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

Leukemia, 2010-12, Vol.24 (12), p.2072-2079

2010

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Hematological oncology, 2023-06, Vol.41 (S2), p.62-63

2023

Volltextzugriff (PDF)

SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL

Hematological oncology, 2023-06, Vol.41 (S2), p.165-166

2023

Volltextzugriff (PDF)

SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY

Hematological oncology, 2023-06, Vol.41 (S2), p.117-119

2023

Volltextzugriff (PDF)

The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison

Annals of oncology, 2014-01, Vol.25 (1), p.200-206

2014

Volltextzugriff (PDF)

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

Bone marrow transplantation (Basingstoke), 2015-10, Vol.50 (10), p.1279-1285

2015

Volltextzugriff (PDF)

R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL

Hematological oncology, 2023-06, Vol.41 (S2), p.50-51

2023

Volltextzugriff (PDF)

Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis

Haematologica (Roma), 2010-12, Vol.95 (12), p.2047-2055

2010

Volltextzugriff (PDF)

MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance

Leukemia, 2013-02, Vol.27 (2), p.353-361

2013

Volltextzugriff (PDF)

P630: TARGETING NEGATIVE REGULATION OF MAPK SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA

HemaSphere, 2022-06, Vol.6, p.528-529

2022

Volltextzugriff (PDF)

Dissection of CD20 regulation in lymphoma using RNAi

Leukemia, 2016-12, Vol.30 (12), p.2409-2412

2016

Volltextzugriff (PDF)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Leukemia, 2013-09, Vol.27 (9), p.1949-1952

2013

Volltextzugriff (PDF)

71: Targeted cancer genetics

European journal of cancer (1990), 2014-07, Vol.50, p.S17-S18

2014

Volltextzugriff (PDF)

535: Small RNA sequencing identifies microRNAs involved in B-cell receptor signaling in chronic lymphocytic leukemia

European journal of cancer (1990), 2014-07, Vol.50, p.S129-S129

2014

Volltextzugriff (PDF)

1 – 25 von 1.307

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.010)
Mit Volltextzugriff
(1.109)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.125)
Deutsch
(186)
Japanisch
(70)
Französisch
(2)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(604)
Humans
(508)
Life Sciences & Biomedicine
(501)
Male
(234)
Female
(228)
Middle Aged
(161)
Adult
(155)
Biological And Medical Sciences
(140)
Hematology
(130)
Medical Sciences
(125)
Aged
(117)
Anesthesiology
(80)
Oncology
(78)
Technology
(75)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(73)
Mutation
(69)
Child
(60)
Neurosciences & Neurology
(60)
General & Internal Medicine
(59)
Adolescent
(58)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia

131 INVITED Chronic Lymphocytic Leukaemia (CLL)

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

The impact of SF3B1 mutations in CLL on the DNA-damage response

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL

SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY

The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL

Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis

MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance

P630: TARGETING NEGATIVE REGULATION OF MAPK SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA

Dissection of CD20 regulation in lymphoma using RNAi

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

71: Targeted cancer genetics

535: Small RNA sequencing identifies microRNAs involved in B-cell receptor signaling in chronic lymphocytic leukemia

Suchergebnisse filtern